210 related articles for article (PubMed ID: 34297048)
21. Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial.
Tournilhac O; Le Garff-Tavernier M; Nguyen Quoc S; Forcade E; Chevallier P; Legrand-Izadifar F; Laurent Damaj G; Michonneau D; Tomowiak C; Borel C; Orvain C; Turlure P; Redjou R; Guillerm G; Vincent L; Simand C; Lemal R; Quiney C; Combes P; Pereira B; Calvet L; Cabrespine A; Bay JO; Leblond V; Dhédin N; Organization Filo FIL; De Moelle Et de Thérapie Cellulaire Sfgm-Tc SFG
Haematologica; 2021 Jul; 106(7):1867-1875. PubMed ID: 32527951
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Kebriaei P; Detry MA; Giralt S; Carrasco-Yalan A; Anagnostopoulos A; Couriel D; Khouri IF; Anderlini P; Hosing C; Alousi A; Champlin RE; de Lima M
Blood; 2007 Nov; 110(9):3456-62. PubMed ID: 17652620
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
Machaczka M; Johansson JE; Remberger M; Hallböök H; Malm C; Lazarevic VLj; Wahlin A; Omar H; Juliusson G; Kimby E; Hägglund H
Leuk Lymphoma; 2012 Sep; 53(9):1699-705. PubMed ID: 22335529
[TBL] [Abstract][Full Text] [Related]
24. Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome.
Park SS; Jeon YW; Min GJ; Park S; Yahng SA; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Lee S; Kim HJ; Min CK; Cho SG; Lee JW; Kim YJ
Biol Blood Marrow Transplant; 2019 Jan; 25(1):63-72. PubMed ID: 30103018
[TBL] [Abstract][Full Text] [Related]
25. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease.
Boyiadzis M; Foon KA; Pavletic S
Expert Opin Biol Ther; 2007 Dec; 7(12):1789-97. PubMed ID: 18034645
[TBL] [Abstract][Full Text] [Related]
26. Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.
Hebenstreit K; Iacobelli S; Leiblein S; Eisfeld AK; Pfrepper C; Heyn S; Vucinic V; Franke GN; Krahl R; Fricke S; Becker C; Pönisch W; Behre G; Niederwieser D; Lange T
Leuk Lymphoma; 2014 Jun; 55(6):1274-80. PubMed ID: 23964650
[TBL] [Abstract][Full Text] [Related]
27. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
28. Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor.
Leung AY; Tse E; Hwang YY; Chan TS; Gill H; Chim CS; Lie AK; Kwong YL
Am J Hematol; 2013 Jun; 88(6):485-91. PubMed ID: 23512868
[TBL] [Abstract][Full Text] [Related]
29. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Rodríguez-Arbolí E; Labopin M; Tischer J; Brecht A; Ganser A; Finke J; Blau IW; Kröger N; Kalhs P; Forcade E; Bunjes D; Spyridonidis A; Savani B; Nagler A; Mohty M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2165-2173. PubMed ID: 32717436
[TBL] [Abstract][Full Text] [Related]
30. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
[TBL] [Abstract][Full Text] [Related]
31. Reduced intensity versus full myeloablative stem cell transplant for advanced CLL.
Peres E; Braun T; Krijanovski O; Khaled Y; Levine JE; Yanik G; Kato K; Mineishi S
Bone Marrow Transplant; 2009 Nov; 44(9):579-83. PubMed ID: 19308041
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning.
Brammer JE; Khouri I; Gaballa S; Anderlini P; Tomuleasa C; Ahmed S; Ledesma C; Hosing C; Champlin RE; Ciurea SO
Biol Blood Marrow Transplant; 2016 Mar; 22(3):493-8. PubMed ID: 26497906
[TBL] [Abstract][Full Text] [Related]
33. Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.
Gribben JG; Hosing C; Maloney DG
Biol Blood Marrow Transplant; 2011 Jan; 17(1 Suppl):S63-70. PubMed ID: 21195313
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
Elnair R; Ellithi M; Kallam A; Shostrom V; Bociek RG
Ann Hematol; 2021 Oct; 100(10):2513-2519. PubMed ID: 34279675
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
36. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
37. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.
Abdul Wahid SF; Ismail NA; Mohd-Idris MR; Jamaluddin FW; Tumian N; Sze-Wei EY; Muhammad N; Nai ML
Stem Cells Dev; 2014 Nov; 23(21):2535-52. PubMed ID: 25072307
[TBL] [Abstract][Full Text] [Related]
38. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.
Efebera YA; Qureshi SR; Cole SM; Saliba R; Pelosini M; Patel RM; Koca E; Mendoza FL; Wang M; Shah J; Alousi A; Hosing C; Popat U; Kebriaei P; Anderlini P; Khouri IF; Champlin R; Giralt S; Qazilbash MH
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1122-9. PubMed ID: 20178853
[TBL] [Abstract][Full Text] [Related]
39. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
40. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO).
Candoni A; Rambaldi A; Fanin R; Velardi A; Arcese W; Ciceri F; Lazzarotto D; Lussana F; Olivieri J; Grillo G; Parma M; Bruno B; Sora F; Bernasconi P; Saccardi R; Foà R; Sessa M; Bresciani P; Giglio F; Picardi A; Busca A; Sica S; Perruccio K; Zucchetti E; Diral E; Iori AP; Colombo AA; Tringali S; Santarone S; Irrera G; Mancini S; Zallio F; Malagola M; Albano F; Carella AM; Olivieri A; Tecchio C; Dominietto A; Vacca A; Sorasio R; Orciuolo E; Risitano AM; Leotta S; Cortelezzi A; Mammoliti S; Oldani E; Bonifazi F;
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2388-2397. PubMed ID: 31400502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
